Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Emerging Therapies
New Long-Acting Interferon Effective and Safe in Polycythemia Vera
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
April 2017, Vol 8, No 2
San Diego, CA—Ropeginterferon alfa-2b, an investigational, long-acting, mono-pegylated interferon was noninferior to hydroxyurea in achieving complete hematologic response and with superior tolerability to hydroxyurea in the treatment of patients with polycythemia vera, according to the final results of the phase 3 PROUD-PV clinical trial presented by Heinz Gisslinger, MD, Medical University of Vienna, Austria, at the 2016 American Society of Hematology meeting.
Read Article
CAR-Targeting CD22 an Effective Salvage Therapy in Relapsed Pediatric Acute Lymphoblastic Leukemia
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
April 2017, Vol 8, No 2
San Diego, CA—Chimeric antigen receptor (CAR)-targeting CD22 therapy induced clinical responses and a high rate of complete remission in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL), including patients who had received anti-CD19 CAR T-cell therapy, said Terry J. Fry, MD, Hematologic Malignancies Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), at the 2016 American Society of Hematology meeting. These findings create the opportunity for bispecific or multispecific CAR T-cell targeting.
Read Article
Plethora of Targeted Agents in the Oncology Pipeline
By
David Knight
Emerging Therapies
,
Personalized Medicine
December 2016, Vol 7, No 11
Washington, DC—The oncology pipeline is bustling and shows no sign of slowing down anytime soon, said Anita Dopkosky, RPh, MS, Director, National Accounts, Walgreens, Pittsburgh, PA, at the Sixth Annual Conference of the Association for Value-Based Cancer Care. She provided an overview of key drugs in the oncology pipeline.
Read Article
The Oncology Drug Pipeline Shows No Evidence of Slowing Down
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Oral and poster presentations of several promising agents in early- and late-phase clinical trials dotted the program at ASCO 2016. The presentations included studies with positive findings associated with many investigational therapies, including first-in-class therapies such as chimeric antigen receptor (CAR) T-cells for the treatment of patients with B-cell malignancies or acute myeloid leukemia (AML); a vaccine (galinpepimut-S) for the treatment of patients with AML; and a chimeric monoclonal antibody against claudin 18.2 for the treatment of patients with advanced gastric cancers.
Read Article
“Smart Bomb” First-in-Class Drug Rova-T Promising Novel Therapy for Small-Cell Lung Cancer
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
The first-in-class antibody-drug conjugate rovalpituzumab tesirine (Rova-T) may be a new treatment option for patients with small-cell lung cancer (SCLC), which has a very poor prognosis and few treatment options. Rova-T is particularly promising in SCLC tumors that overexpress the delta-like (DLL) 3 protein, according to first-in-human study results presented at ASCO 2016.
Read Article
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
June 2016, Vol 7, No 5
Read Article
Entrectinib Shows Strong Activity Against a Range of Rare Solid Tumors with Molecular Abnormalities
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
June 2016, Vol 7, No 5
Read Article
Venetoclax Shows Strong Activity in CLL
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
February 2016, Vol 7, No 1
The oral, investigational, small-molecule BCL-2 inhibitor venetoclax has shown excellent and durable responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). All patients in the trial harbored the 17p deletion (del 17p), which signals poor prognosis.
Read Article
The Hematologic Drug Pipeline: Exciting New Treatment Options Looming
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
February 2016, Vol 7, No 1
Many presentations at ASH 2015 focused on novel therapies currently in development for the treatment of patients with hematologic malignancies, including a second generation of new agents recently approved by the FDA for a variety of hematologic cancers.
Read Article
Midostaurin the First Targeted Therapy to Improve Survival in AML: Potentially Practice-Changing
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
February 2016, Vol 7, No 1
The multikinase inhibitor midostaurin is the first targeted therapy to improve overall survival (OS) in patients with acute myeloid leukemia (AML) and the
FLT3
mutation.
Read Article
Page 4 of 6
1
2
3
4
5
6
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma